Keros Therapeutics, Inc. 8-K

What Happened

• On January 9, 2026, Keros Therapeutics, Inc. (KROS) filed a Form 8‑K under Item 7.01 (Regulation FD Disclosure) to announce an updated corporate presentation for use in investor, analyst and other meetings. A copy of the presentation dated January 2026 is attached as Exhibit 99.1 and is available on the company’s website.
• The filing states the information is being furnished (not “filed”) and therefore is not subject to Section 18 liabilities of the Securities Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Filing date: January 9, 2026 (Form 8‑K).
• Exhibit: 99.1 — Corporate Presentation dated January 2026 (posted on Keros’ website).
• Reported under Item 7.01 (Regulation FD Disclosure); exhibit listing also included under Item 9.01.
• The company explicitly notes the furnished material is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• Investors and analysts who follow Keros should review the attached presentation for the company’s latest corporate overview, strategy, pipeline or other disclosures made to the market in investor-facing materials.
• Because the presentation is furnished (not filed), it has limited legal effect under the Exchange Act and is not automatically incorporated into the company’s other SEC filings; investors should rely on the presentation itself for any new information.